TrialDiabetes care2012

Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).

Itamar Raz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.